| __timestamp | Exelixis, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 189101000 | 94231000 |
| Thursday, January 1, 2015 | 96351000 | 146394000 |
| Friday, January 1, 2016 | 95967000 | 188272000 |
| Sunday, January 1, 2017 | 112171000 | 166707000 |
| Monday, January 1, 2018 | 182257000 | 401843000 |
| Tuesday, January 1, 2019 | 336964000 | 560909000 |
| Wednesday, January 1, 2020 | 547851000 | 722343000 |
| Friday, January 1, 2021 | 693716000 | 771182000 |
| Saturday, January 1, 2022 | 891813000 | 877090000 |
| Sunday, January 1, 2023 | 1044071000 | 877387000 |
Data in motion
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Sarepta Therapeutics, Inc. and Exelixis, Inc. have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Exelixis, Inc. increased its R&D expenses by over 450%, peaking in 2023 with a staggering $1.04 billion. This aggressive investment reflects their strategic focus on expanding their oncology pipeline. Meanwhile, Sarepta Therapeutics, Inc. has shown a steady increase, with a notable 830% rise from 2014 to 2022, reaching $877 million. This growth underscores their dedication to advancing genetic medicine.
These trends highlight the dynamic nature of the biotech industry, where strategic R&D investments can drive innovation and potentially lead to groundbreaking therapies.
R&D Spending Showdown: Novartis AG vs Sarepta Therapeutics, Inc.
Research and Development Expenses Breakdown: Biogen Inc. vs Sarepta Therapeutics, Inc.
Research and Development Investment: Neurocrine Biosciences, Inc. vs Exelixis, Inc.
Analyzing R&D Budgets: Intra-Cellular Therapies, Inc. vs Sarepta Therapeutics, Inc.
Analyzing R&D Budgets: Dr. Reddy's Laboratories Limited vs Sarepta Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Exelixis, Inc.
R&D Spending Showdown: Sarepta Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Comparing Innovation Spending: Sarepta Therapeutics, Inc. and Mesoblast Limited
Exelixis, Inc. or TG Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ultragenyx Pharmaceutical Inc.
Analyzing R&D Budgets: Exelixis, Inc. vs Veracyte, Inc.
Exelixis, Inc. or Mesoblast Limited: Who Invests More in Innovation?